Department of Biotechnology and Molecular Medicine, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Student Research Committee, Arak University of Medical Sciences, Arak, Iran.
PLoS One. 2024 Nov 1;19(11):e0312250. doi: 10.1371/journal.pone.0312250. eCollection 2024.
Glioma is a type of cancer that affects the central nervous system and necessitates a non-invasive diagnostic and prognostic assessment. MicroRNAs (miRNAs) play a crucial role in glioma and can provide valuable information about the prognosis of patients with this condition. MiR-124 is associated with molecules that play crucial roles in cellular processes, and any disruption in its expression can have a detrimental effect on cells, potentially leading to cancer. Therefore, miR-124 can be a valuable biomarker for diagnosis and prognosis in glioma. This review aims to highlight the role of miR-124 as a diagnostic and prognostic factor in glioma. To address this issue, we systemically reviewed and used various search strategies across three databases (PubMed, Web of Science and Scopus) and then yielded 3046 records from inception to September 2023. Records that did not meet our inclusion criteria were excluded. Following the screening process, our analysis included and summarized 13 eligible studies that not only measured miR-124 in serum, plasma, and tissue of glioma patients but also provided insights intomiR-124 as a prognostic and diagnostic biomarker. Thirteen studies were included for diagnostic accuracy, and five were considered for prognostic importance of miR-124. Based on our results, a single study showed an increase in miR-124 levels in exosomes obtained from patient serum, whereas the data from the 12 studies analyzed consistently pointed towards a reduction in miR-124 levels in various glioma samples. In conclusion, our findings suggest that miR-124 may be a useful diagnostic and prognostic biomarker in glioma. However, further investigations are required to draw more definitive conclusions.
神经胶质瘤是一种影响中枢神经系统的癌症，需要进行非侵入性的诊断和预后评估。microRNAs（miRNAs）在神经胶质瘤中起着至关重要的作用，可以提供有关患者预后的有价值信息。miR-124 与在细胞过程中发挥关键作用的分子有关，其表达的任何中断都可能对细胞产生不利影响，从而导致癌症。因此，miR-124 可以作为神经胶质瘤诊断和预后的有价值的生物标志物。本综述旨在强调 miR-124 作为神经胶质瘤诊断和预后因素的作用。为了解决这个问题，我们系统地回顾了三个数据库（PubMed、Web of Science 和 Scopus）中的各种搜索策略，并在 2023 年 9 月之前从最初到现在生成了 3046 条记录。不符合我们纳入标准的记录被排除在外。在筛选过程之后，我们的分析包括并总结了 13 项符合条件的研究，这些研究不仅测量了神经胶质瘤患者血清、血浆和组织中的 miR-124，还提供了有关 miR-124 作为预后和诊断生物标志物的见解。有 13 项研究用于评估诊断准确性，有 5 项研究用于评估 miR-124 的预后重要性。根据我们的研究结果，有一项研究表明患者血清中提取的外泌体中 miR-124 水平升高，而分析的 12 项研究的数据均一致表明各种神经胶质瘤样本中 miR-124 水平降低。总之，我们的研究结果表明，miR-124 可能是神经胶质瘤有用的诊断和预后生物标志物。然而，需要进一步的研究来得出更明确的结论。
